Still, the TARGIT-A demonstrated a roughly 5% reduction in control, whereas the ELIOT trial showed a quite significant 15% loss in control rate [ 31 ].
← all excerpts
Real World and Public Health Perspectives of Intraoperative Radiotherapy in Early-Stage Breast Cancer: A Multidisciplinary Analysis Beyond the Statistical Facts.
1
—
—